Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
about
Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in miceImmunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infectionIntranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.Heat-killed Trypanosoma cruzi induces acute cardiac damage and polyantigenic autoimmunityDeficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challengeImmune responses to gp82 provide protection against mucosal Trypanosoma cruzi infectionECG detection of murine chagasic cardiomyopathy.Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas diseaseCostimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruziDNA vaccines against tropical parasitic diseases.Specific humoral and cellular immunity induced by Trypanosoma cruzi DNA immunization in a canine model.A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.Lethal NK-mediated inflammation induced by IL-12 in the absence of polymorphic and nonpolymorphic MHC class I molecules.Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease.Optimizing vaccine development.Differential interleukin-8 and nitric oxide production in epithelial cells induced by mucosally invasive and noninvasive Trypanosoma cruzi trypomastigotes.Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients.Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype.Trypanosoma cruzi Entrance through Systemic or Mucosal Infection Sites Differentially Modulates Regional Immune Response Following Acute Infection in Mice.Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.Cardiac damage induced by immunization with heat-killed Trypanosoma cruzi is not antibody mediated.Cytokine serum levels in patients infected by human immunodeficiency virus with and without Trypanosoma cruzi coinfection.Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection.Natural CD4+ T-cell responses against Trypanosoma cruzi KMP-11 protein in chronic chagasic patients
P2860
Q24602785-21757096-148D-41D7-9477-137BBD7C7970Q30452989-03481B6B-7F8B-4202-BF85-C32AF4EB0684Q33675887-585BDE06-5751-4D3C-A45C-CA7D70C6B281Q33809208-84880895-209F-416B-AB57-E6068065C7A0Q35071882-9678C242-4ECF-4CAE-B0F9-CF55D876A448Q35073839-82093B60-E7FC-4F51-AD72-632311BDB5A3Q35139381-FCF4394A-DF1E-43BF-8049-4EA58BAD3870Q35148043-2CFD668A-1818-4555-9C56-90F3C8AF50F5Q35148047-E6935BE1-B7B5-467D-AC6E-762ED48B55C5Q35149267-B9410AB3-318F-43D6-A0BD-8CC68C92C514Q35565140-DC572FB4-3217-4C19-ACCE-2567578451B0Q36136972-289AFAAF-1D99-4C7C-AEA1-81F37B95D3B3Q36151179-7B804168-5F86-42A7-99C1-4EBC986D94BBQ36238733-E4494DBD-5A8F-455B-9432-C44CDB9B0F18Q36694552-53525CC6-7B85-4FCB-89E8-E632B84CB1DFQ36735672-54CCC55E-6F4B-4FA3-B1AB-8423EE079F1DQ37164883-CBA0DEC5-6F2F-45C0-A890-731F27F2BC6BQ37384778-DD3CF447-0C81-4105-A66A-5C7556714578Q37883493-2AD09747-3360-423D-91A4-ED026E6726F9Q39863865-A6C64800-31F5-4C13-BC13-8B61C0A0A3BEQ40309242-01B3D9CD-B574-4026-AFE0-87436BFB6747Q41709177-D0DE9024-9738-4948-A61B-E08E599ADDC7Q41935309-4B04A423-A54B-41FF-99C9-F2DC1A15421BQ42957081-31BA73D5-D8A2-4646-9E59-43F9FCD6E008Q44113294-01C59A48-59F4-47A2-9F0F-269ACECB6F5CQ45420858-DDD56E6C-AC22-45A3-B677-6C12647F89B3Q55226818-C42C0C90-16C2-47C3-B7B3-42ECB874B611Q57596977-BC7F2204-C9A7-472F-BD5B-5F13B7BC89FE
P2860
Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@en
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@nl
type
label
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@en
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@nl
prefLabel
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@en
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@nl
P2860
P1476
Type 1 immunity provides optim ...... Trypanosoma cruzi challenges.
@en
P2093
C S Eickhoff
P2860
P304
P356
10.1128/IAI.70.12.6715-6725.2002
P407
P577
2002-12-01T00:00:00Z